Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) Sees Significant Decrease in Short Interest

Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) was the target of a large decline in short interest during the month of October. As of October 31st, there was short interest totalling 887,500 shares, a decline of 14.5% from the October 15th total of 1,038,600 shares. Based on an average daily trading volume, of 100 shares, the days-to-cover ratio is presently 8,875.0 days.

Swedish Orphan Biovitrum AB (publ) Trading Down 2.0 %

Shares of OTCMKTS:BIOVF opened at $31.38 on Monday. The company has a debt-to-equity ratio of 0.30, a quick ratio of 0.49 and a current ratio of 0.73. Swedish Orphan Biovitrum AB has a twelve month low of $21.05 and a twelve month high of $32.25. The firm has a 50 day simple moving average of $30.89 and a 200-day simple moving average of $27.77.

Swedish Orphan Biovitrum AB (publ) Company Profile

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); VONJO for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis; Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still’s disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection.